logo
Automaker achieves unprecedented breakthrough that could alter how we think about electric cars: 'It's nothing less than a game-changer'

Automaker achieves unprecedented breakthrough that could alter how we think about electric cars: 'It's nothing less than a game-changer'

Yahoo2 days ago

China's BYD just flipped the electric vehicle charging conversation on its head with a game-changing demonstration that could make EVs more convenient than ever.
In a high-profile test in Beijing, BYD delivered 262 miles of range to its Han L electric sedan in under five minutes using its new Megawatt charging system, as reported by InsideEVs.
That's about the time it takes to fill up with gas, and it could completely reshape how we think about electric cars.
For many people, EV charging still feels like a hassle. But BYD's new tech, built on its proprietary Super e-Platform, might just change that perception.
This 1,000-volt setup, the first of its kind in mass-produced EVs, allows energy to move ultra-fast while staying safe thanks to a redesigned battery and cooling system.
According to InsideEVs, BYD had to build nearly every part of the system in-house, from silicon-carbide power chips to upgraded motors and power distribution components.
It even redesigned the charging plug to make it smaller and easier to handle.
The Han L and its SUV sibling, the Tang L, can also draw power from two fast chargers at the same time, maximizing their charging potential when Megawatt stations aren't available.
"It's nothing less than a game-changer for the entire space," the author wrote.
When charging an EV is as quick and easy as pumping gas, the idea of going electric becomes much more appealing.
Would you buy an EV if it only took 5 minutes to charge?
Sign me up
No way
Depends on the cost
Depends how much range it has
Click your choice to see results and speak your mind.
Shorter stops also mean more time on the road for commuters and businesses, and fewer emissions mean cleaner air for everyone.
These faster systems could also help delivery fleets, rideshare drivers, and public transit reduce downtime, saving money and energy.
If you charge at home, the benefits multiply. Adding rooftop solar panels lets you fuel your EV with clean sunshine, cutting costs and pollution at the same time.
Tools such as EnergySage make it easy to compare vetted solar quotes and start saving.
BYD is one of the many companies making a splash. Innovators such as Aptera are working on solar-powered vehicles that barely need to plug in at all.
Startups developing heat-resistant battery backups are also helping ensure that clean energy stays available when people need it most.
Even retailers such as Walmart are adding more chargers to their parking lots, helping everyday drivers power up while they shop.
With more than 500 Megawatt chargers already operating in China and thousands more planned, BYD is showing what's possible.
While it may take some time for this tech to reach the U.S., BYD's five-minute charging breakthrough sets a new bar for what EV drivers everywhere can eventually expect.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

Yahoo

time3 hours ago

  • Yahoo

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

- A refreshed global brand signals JCR's expanded international presence and unwavering focus on rare and genetic diseases worldwide - HYOGO, Japan, June 06, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. "At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases." The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

Business Wire

time3 hours ago

  • Business Wire

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. 'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.' The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:

China Market Update: Meituan Receives Outsized Mainland Flow, Week In Review
China Market Update: Meituan Receives Outsized Mainland Flow, Week In Review

Forbes

time3 hours ago

  • Forbes

China Market Update: Meituan Receives Outsized Mainland Flow, Week In Review

CLN KraneShares Asian equities ended a positive week mixed, led by India following a larger-than-expected rate cut (0.50% vs. 0.25%). South Korea was closed for Memorial Day, and Indonesia, Pakistan, and the Philippines were closed for Eid al-Adha, also known as the Feast of Sacrifice, 'a festival to honor the willingness of the Prophet Ibrahim to follow the command of Allah to sacrifice his son.' Hong Kong and Mainland China saw profit taking in recent growth and technology outperformers despite the Trump-Xi call, as some pointed to a lack of details, though President Trump confirmed the US would be represented by Bessent, Lutnick, and Greer at a yet-to-be-determined location. The markets had risen on the chatter of a call in another example of markets' forward-looking nature, i.e., buy the rumor and sell the news. Short-video platform Kuaishou Technology gained +8.44% as the company announced its Kling AI, an AI online video generator, will generate $100 million in revenue by February of 2026. E-commerce names, including Alibaba and which fell -1.44% and -1.45%, as several provinces, including Jiangsu and Chongqing, announced they had run out of home appliance subsidies to be used in the 618 (June 18) E-Commerce sales event. I suspect the issue will be resolved in short order. Electric vehicle (EV) stocks, including BYD, which fell -2.18%, Xiaomi, which fell -2.12%, Li Auto, which was flat, and XPeng, which fell -1.77%, were mostly lower on yesterday's news of the Ministry of Industry and Information Technology's (MIIT) price war warning. It seems like a positive to me! Value plays such as telecom and precious metals outperformed. Mainland investors bought the dip in Hong Kong, with $862 million worth of net buying via Southbound Stock Connect. Meituan saw another day of strong net inflow, as 13.54% of shares are now held by Mainland investors, up from only 11% earlier this year. I don't know what's driving Mainland investors' significant Meituan inflows, at 200 million shares bought, but it is interesting. Like Hong Kong, value stocks outperformed growth stocks in Shanghai and Shenzhen, as oil, precious metals, and aerospace stocks rallied. May's consumer price index (CPI) and producer price index (PPI) will be reported on Sunday. The US Treasury did not label China a currency manipulator, though it does highlight the strength of the Renminbi versus the US dollar, recently. CNY hit a low of 7.34 CNY per USD on April 9th following Liberation Day, though CNY has rallied to 7.18 (CNY is quoted USD per CNY, so a decline is appreciation versus the US dollar). More surprising is that Hong Kong and US-listed China stocks haven't rallied more due to the appreciation of the underlying businesses, as their revenues are denominated in Renminbi. Hopefully, we'll see this move soon! New Content Read our latest article: Navigating Global Crosswinds: Carbon Markets Respond to Tariff Tactics and Executive Orders Please click here to read Chart1 KraneShares Chart2 KraneShares Chart3 KraneShares Chart4 KraneShares Chart5 KraneShares Chart6 KraneShares

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store